Kurssprung nach langer Abwärtstendenz
eröffnet am: | 01.06.16 11:10 von: | Saramee |
neuester Beitrag: | 25.04.21 01:09 von: | Mandyyriga |
Anzahl Beiträge: | 139 | |
Leser gesamt: | 36637 | |
davon Heute: | 8 | |
bewertet mit 1 Stern |
||
|
01.06.16 11:10
#1
Saramee
Kurssprung nach langer Abwärtstendenz
Die Biotechaktie ist gerade am hochspringen, nachdem sie vorher nur die Richtung Süden kannte. Kennt jemand die Aktie und weiß, warum die plötzlich ausbricht?
113 Postings ausgeblendet.
25.08.17 17:26
#117
Dölauer
Liegen die Nerven blank
oder ist es die Enttäuschung, dass gewandelt werden kann zu recht niedrigen Kursen oder/und geben einige ihre Aktien einfach billig ab. Aus welchen Gründen auch immer.
In Deutschland ist ja eh wenig Handel. Das es so schnell runter geht, hätte ich nicht gedacht.
In Deutschland ist ja eh wenig Handel. Das es so schnell runter geht, hätte ich nicht gedacht.
26.08.17 12:42
#118
Dölauer
Meldung vom 24.08.2017
Immune Pharma inks convertible debt deal at $1.75; shares slump 45%
Aug. 24, 2017 9:38 AM ET|About: Immune Pharmaceuticals... (IMNP)|By: Douglas W. House, SA News Editor
•Immune Pharmaceuticals (IMNP -45%) enters into an agreement with institutional investors for the sale of $858K aggregate principal amount of convertible debentures. The conversion price will be $1.75 per common share but could drop as low as $1.00 under certain conditions.
•Net proceeds should be $660K.
•The company has also lowered the conversion price of an earlier (May 4) convertible debt deal to $1.30 from $2.89 in order to secure investors' support for the new transaction.
•Yesterday's close was $2.20.
Immune Pharma inks convertible debt deal at $1.75; shares slump 45%
Aug. 24, 2017 9:38 AM ET|About: Immune Pharmaceuticals... (IMNP)|By: Douglas W. House, SA News Editor
•Immune Pharmaceuticals (IMNP -45%) enters into an agreement with institutional investors for the sale of $858K aggregate principal amount of convertible debentures. The conversion price will be $1.75 per common share but could drop as low as $1.00 under certain conditions.
•Net proceeds should be $660K.
•The company has also lowered the conversion price of an earlier (May 4) convertible debt deal to $1.30 from $2.89 in order to secure investors' support for the new transaction.
•Yesterday's close was $2.20.
06.01.18 23:36
#130
Balu4u
report final results in early 2018
Story in BioWorld by Michael Fitzhugh.
Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an FDA orphan designation for the candidate, expects to complete the proof-of-concept study and report final results in early 2018. Company shares (NASDAQ:IMNP) rose 16.7 percent to $1.40 by Wednesdays close.
Download PDF
Story in BioWorld by Michael Fitzhugh.
Preliminary data on three additional patients enrolled in a small open-label study of Immune Pharmaceuticals Inc.s bertilimumab, an experimental treatment for the rare blistering disease bullous pemphigoid (BP), continued to suggest it may offer an effective alternative to systemic corticosteroids, a standard but imperfect therapy for the condition. Immune, which is seeking an FDA orphan designation for the candidate, expects to complete the proof-of-concept study and report final results in early 2018. Company shares (NASDAQ:IMNP) rose 16.7 percent to $1.40 by Wednesdays close.
Download PDF